Developer docs
API playgroundTry for free, no card

Search company profiles

Greenstone Biosciences

Full company profile

uuid0000ev4

Namestring
Greenstone Biosciences
Legal namestring
Greenstone Biosciences, Inc.
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Greenstone Biosciences is a private, Palo Alto-based drug discovery platform founded in 2021 that supplies human induced pluripotent stem cell (iPSC)-derived products, 3D organoid models, and AI-enabled preclinical services to pharmaceutical, biotechnology, and academic customers. The company's core asset is what it describes as the world's largest human iPSC biobank, generated from more than 2,500 individuals and including the largest collection of iPSCs derived from rare orphan disease patients. The product portfolio spans standardized cell products (iPSC lines, ventricular and atrial cardiomyocytes, fibroblasts, smooth muscle cells, macrophages, endothelial cells, and intestinal epithelial cells), 3D organoids (cardiac, pancreatic islet, gut, and vascularized variants), and contract research services including PBMC collection and reprogramming, custom differentiation, genetic engineering, high-throughput screening, clinical-trial-in-a-dish, CARTOX (hERG) cardiac safety, hepatotoxicity, gut barrier, and pancreatic islet functional assays. The platform is positioned around the FDA's New Approach Methodologies (NAMs) agenda, citing the FDA Modernization Act 2.0 (2022) and the 2025 phase-out of animal testing for monoclonal antibodies as demand catalysts.

The company's commercial model operates through three channels: a direct e-commerce storefront selling per-vial products at $200 (iPSCs) to $2,500–$3,100 (organoids) with academic pricing; quote-based custom services for enterprise and pharma clients; and longer-cycle drug discovery partnerships. Greenstone has signed high-profile technology integrations with Intel (Edge AI infrastructure, announced at Computex 2026), NVIDIA (AI drug toxicity models), and Illumina (genomics), alongside strategic co-development deals with Neolaia Bio (IBD), Cibus Therapeutics (chronic pancreatitis, CBT-101), and Creative Medical Technology (BioDefense Veterans Initiative). The ADMET-AI platform (admet.ai.greenstonebio.com) provides machine-learning-based absorption, distribution, metabolism, excretion, and toxicity prediction layered on top of the wet-lab biobank. The company is co-founded by Dr. Joseph C. Wu, Director of the Stanford Cardiovascular Institute, and is headquartered at Stanford Research Park, Palo Alto, California.

Short descriptiontext

Greenstone Biosciences is a Palo Alto-based drug discovery platform that supplies human iPSC-derived cells, 3D organoids, and AI-enabled preclinical services to pharmaceutical, biotechnology, and academic customers, anchored by the world's largest human iPSC biobank of more than 2,500 individuals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
iPSC drug discovery, organoid screening services, human cell models, preclinical safety testing, ADMET prediction platform
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biotechnology Drug Discovery Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1iPSC and Cell Products
TypeOne Time License
Description

Sale of standardized human iPSC lines, differentiated cells (cardiomyocytes, fibroblasts, smooth muscle cells, macrophages, endothelial cells, epithelial cells), and organoid products for research and drug discovery applications

greenstonebio.com
2Custom Services
TypeProfessional Services
Description

Customized services including PBMC collection and iPSC reprogramming, genetically engineered iPSCs, clinical trial in a dish, CARTOX hERG toxicity assays, hepatotoxicity screens, and specialized disease modeling

greenstonebio.com
3Drug Discovery Partnerships
TypeSubscription Recurring
Description

Strategic collaborations with pharmaceutical and biotech companies for drug discovery programs using human iPSC models and AI platforms

greenstonebio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details4 tiers
1iPSC - Academia product line
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$200 per vial for undifferentiated iPSC lines (≥2 million viable cells)

greenstonebio.com
2Differentiated cell products
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$1,100-$1,800 per vial for differentiated cells (cardiomyocytes, fibroblasts, smooth muscle cells, macrophages, endothelial cells, epithelial cells) with quantities of 2-5 million viable cells

greenstonebio.com
3Organoid products
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$2,500-$3,100 per vial for cardiac and gut organoids; vascularized variants at premium pricing

greenstonebio.com
4Custom services
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing for custom differentiated iPSCs, genetically engineered iPSCs, PBMC collection, clinical trial in a dish, and specialized assays (CARTOX, hepatotoxicity screening)

greenstonebio.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Greenstone Biosciences operates a human induced pluripotent stem cell (iPSC) drug discovery platform anchored by what it claims is the world's largest human iPSC biobank of 2,500+ individuals, including the largest collection of rare orphan disease iPSCs. It sells standardized iPSC lines, differentiated cell types, and 3D organoids, and provides contract research services spanning iPSC reprogramming, genome editing, high-throughput screening, ADMET-AI predictive analytics, and cardiac/hepatic safety assays for pharmaceutical and academic clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Up to 92% of drugs fail in human trials despite preclinical testing in animals
+1 more record
Product overview1 text field

Greenstone Biosciences operates as a biotech company offering a comprehensive platform of human iPSC-based products and services for drug discovery. The core offering centers on the world's largest human iPSC biobank (2,500+ individuals), which powers two main product lines: hiPSC-derived cells (ventricular/atrial cardiomyocytes, fibroblasts, smooth muscle cells, macrophages, endothelial cells, and intestinal epithelial cells) and 3D organoids (cardiac, pancreatic, gut organoids with vascularized variants). The portfolio is complemented by a suite of contract research services including iPSC reprogramming, custom differentiation, high-throughput screening, and specialized toxicity assays (CARTOX/hERG, hepatotoxicity). The ADMET-AI platform adds AI-powered predictive analytics for absorption, distribution, metabolism, excretion, and toxicity evaluation. Together, these products and services enable human-centric drug discovery that reduces reliance on animal testing and aligns with FDA New Approach Methodologies (NAMs) guidance.

Product and service13 records
1ADMET-AI
CategoryAI Software Platform
Description

AI-powered platform for absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction using machine learning to accelerate drug candidate evaluation for pharmaceutical and biotech drug developers.

2hiPSC-Derived Cells
CategoryBiological Product
Description

Human induced pluripotent stem cell-derived cell types including ventricular cardiomyocytes, atrial cardiomyocytes, fibroblasts, smooth muscle cells, macrophages, endothelial cells, and intestinal epithelial cells for disease modeling and drug discovery, sold to academic and pharmaceutical researchers.

3Organoids
CategoryBiological Product
Description

3D organ-like tissue models generated from iPSCs including ventricular cardiac organoids, atrial cardiac organoids, pancreatic islet organoids, gut organoids, vascularized ventricular cardiac organoids, and vascularized atrial cardiac organoids for disease modeling and drug discovery.

4PBMC Collection and iPSC Reprogramming
CategoryCustom Service
Description

Collection of peripheral blood mononuclear cells and reprogramming into induced pluripotent stem cells for research and therapeutic applications, provided as a custom service to research and biotech clients.

5Custom Differentiated iPSCs
CategoryCustom Service
Description

Custom differentiation services to generate specific cell types from iPSC lines for specialized research needs, delivered on a quote basis to academic and pharmaceutical clients.

6Genetically Engineered iPSCs
CategoryCustom Service
Description

Genome editing services (CRISPR/Cas9 and related) to create genetically modified iPSC lines with specific mutations or modifications for disease modeling, sold to research and drug discovery clients.

7High-Throughput Drug Discovery
CategoryCustom Service
Description

Scalable screening service using iPSC-derived cells and organoids for rapid drug candidate evaluation across multiple conditions, delivered to pharmaceutical and biotech clients.

8Cell Village
CategoryCustom Service
Description

Panel of diverse iPSC lines representing population-scale genetic diversity for comprehensive drug testing, offered as a custom service for population-level drug response studies.

9Clinical Trial in a Dish
CategoryCustom Service
Description

Personalized medicine service using patient-derived iPSCs to predict individual drug responses before clinical trials, delivered to pharmaceutical and biotech clients.

10CARTOX (hERG Toxicity Assay)
CategoryCustom Service
Description

Cardiac safety screening service assessing hERG potassium channel blockade to predict drug-induced heart rhythm abnormalities, delivered to pharmaceutical preclinical safety teams.

11Hepatotoxicity Screen
CategoryCustom Service
Description

Liver toxicity assessment service using human cellular models to predict drug-induced hepatotoxicity during drug development, sold to pharmaceutical preclinical safety teams.

12Functional Assays of Gut Barrier Integrity and Disease Modelling
CategoryCustom Service
Description

Intestinal barrier function assessment and disease modeling service using gut organoids for gastrointestinal drug development, delivered to research and pharmaceutical clients.

13Pancreatic Islet Organoid – Glucose Sensitivity
CategoryCustom Service
Description

Beta-cell function assessment service measuring glucose-stimulated insulin secretion responses in pancreatic islet organoids, delivered to diabetes and metabolic disease researchers.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-02
Description

Strategic collaboration to scale human-centric drug discovery by integrating Greenstone's induced pluripotent stem cell biobank with Intel's Edge AI computing and infrastructure. The partnership aims to accelerate AI-enabled drug discovery, improve drug safety assessment, and advance precision medicine, highlighted during Intel's Computex 2026 keynote.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-02-19
Description

Strategic collaboration to advance inflammatory bowel disease (IBD) drug development using iPSC-derived macrophages and patient-relevant human gut organoid models. Neolaia provides proprietary drug candidates while Greenstone evaluates them using its human-based disease modeling platform.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-12-19
Description

Partnership with Mission: Cure and Greenstone Biosciences to advance CBT-101, a novel therapy for chronic pancreatitis. The collaboration combines drug development, stem cell AI-based discovery, and patient advocacy, aiming to begin clinical trials in 2026.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-10-30
Description

Partnership for the BioDefense Veterans Initiative to address health issues caused by toxic burn pit exposure among U.S. veterans. Greenstone provides molecular and cellular data analysis systems to develop predictive models and treatments using AI-integrated regenerative biodefense.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-25
Description

Collaboration to develop AI models predicting drug toxicity using human cellular systems. The project aims to enhance drug safety testing, reduce reliance on animal testing, and advance precision therapeutics, aligning with FDA's strategic shift to new methodologies.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-24
Description

Collaboration to advance precision drug discovery by integrating Greenstone's iPSC biobank with Illumina's genomics technologies. The partnership aims to generate detailed molecular maps to enhance understanding of disease biology and accelerate drug development across multiple therapeutic areas.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Insitro combines iPSC-derived disease models with machine learning to drive drug discovery partnerships with pharma. It mirrors Greenstone's strategy of integrating iPSC biology, AI/ML, and pharma discovery collaborations, and overlaps on ADMET prediction and target ID workflows.

TypeDirect peer
Description

Ncardia provides human iPSC-derived cell products and services, including iPSC-derived cardiomyocytes, used for cardiac safety and drug discovery. It directly competes with Greenstone's ventricular/atrial cardiomyocytes, CARTOX/hERG assays, and cardiovascular disease modeling offerings.

TypeBroad incumbent
Description

CytoReason provides AI-driven multi-omics data analysis and disease models for pharma R&D, used to accelerate drug discovery and target identification. Its AI/omics platform overlaps with Greenstone's ADMET-AI and Bioinformatics/Multi-Omics positioning for enterprise pharma customers.

TypeDirect peer
Description

BrainXell specializes in iPSC-derived neural cell types for CNS disease modeling and drug discovery. Like Greenstone, it serves academic researchers and pharma with custom differentiated iPSCs, overlapping with Greenstone's broader cell-type catalog and target identification services.

TypeBroad incumbent
Description

Recursion is a publicly listed AI-driven drug discovery platform combining high-throughput biology with proprietary ML. Its larger scale and broader pipeline make it a broad incumbent against Greenstone's AI-drug-discovery ambitions, especially in partnership pitches to large pharma.

6Xilis
TypeEmerging player
Description

Xilis has built a micro-organoid platform for patient-derived drug screening and predictive oncology. While oncology-focused, its micro-organoid platform parallels Greenstone's 3D organoid drug-discovery offering and competes for pharma discovery service budgets.

TypeDirect peer
Description

Emulate offers organ-on-chip and micro-physiological systems used for human-relevant preclinical drug testing. Its organ-Chip platform competes directly with Greenstone's organoid systems for ADMET, hepatotoxicity, and gut barrier integrity services.

TypeDirect peer
Description

Bit.bio has developed an iPSC reprogramming and cell-coding platform that produces human cell types at scale for research and drug discovery. Its deterministic reprogramming approach competes directly with Greenstone's iPSC biobank, custom differentiated iPSCs, and Cell Village offerings.

TypeDirect peer
Description

Cellular Dynamics International, now part of FUJIFILM, is the established leader in commercial iPSC-derived cell products including iCell cardiomyocytes. It is the incumbent against which Greenstone's $200 academic iPSC vials and differentiated cell products are differentiated.

TypeDirect peer
Description

Axol Bioscience manufactures iPSC-derived cell products including cardiomyocytes, neurons, and endothelial cells for disease modeling and drug discovery. Its iPSC-derived cell catalog, especially cardiac and neuronal lines, directly overlaps with Greenstone's hiPSC-Derived Cells and organoid product lines.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Greenstone Biosciences

Biotechnology Drug Discovery Servicesgreenstonebio.com

Greenstone Biosciences is a Palo Alto-based drug discovery platform that supplies human iPSC-derived cells, 3D organoids, and AI-enabled preclinical services to pharmaceutical, biotechnology, and academic customers, anchored by the world's largest human iPSC biobank of more than 2,500 individuals.

What Greenstone Biosciences does

Greenstone Biosciences is a private, Palo Alto-based drug discovery platform founded in 2021 that supplies human induced pluripotent stem cell (iPSC)-derived products, 3D organoid models, and AI-enabled preclinical services to pharmaceutical, biotechnology, and academic customers. The company's core asset is what it describes as the world's largest human iPSC biobank, generated from more than 2,500 individuals and including the largest collection of iPSCs derived from rare orphan disease patients. The product portfolio spans standardized cell products (iPSC lines, ventricular and atrial cardiomyocytes, fibroblasts, smooth muscle cells, macrophages, endothelial cells, and intestinal epithelial cells), 3D organoids (cardiac, pancreatic islet, gut, and vascularized variants), and contract research services including PBMC collection and reprogramming, custom differentiation, genetic engineering, high-throughput screening, clinical-trial-in-a-dish, CARTOX (hERG) cardiac safety, hepatotoxicity, gut barrier, and pancreatic islet functional assays. The platform is positioned around the FDA's New Approach Methodologies (NAMs) agenda, citing the FDA Modernization Act 2.0 (2022) and the 2025 phase-out of animal testing for monoclonal antibodies as demand catalysts.

The company's commercial model operates through three channels: a direct e-commerce storefront selling per-vial products at $200 (iPSCs) to $2,500–$3,100 (organoids) with academic pricing; quote-based custom services for enterprise and pharma clients; and longer-cycle drug discovery partnerships. Greenstone has signed high-profile technology integrations with Intel (Edge AI infrastructure, announced at Computex 2026), NVIDIA (AI drug toxicity models), and Illumina (genomics), alongside strategic co-development deals with Neolaia Bio (IBD), Cibus Therapeutics (chronic pancreatitis, CBT-101), and Creative Medical Technology (BioDefense Veterans Initiative). The ADMET-AI platform (admet.ai.greenstonebio.com) provides machine-learning-based absorption, distribution, metabolism, excretion, and toxicity prediction layered on top of the wet-lab biobank. The company is co-founded by Dr. Joseph C. Wu, Director of the Stanford Cardiovascular Institute, and is headquartered at Stanford Research Park, Palo Alto, California.

Greenstone Biosciences firmographics

Firmographics
Name
Greenstone Biosciences
Legal name
Greenstone Biosciences, Inc.
Website
https://greenstonebio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Greenstone Biosciences is a Palo Alto-based drug discovery platform that supplies human iPSC-derived cells, 3D organoids, and AI-enabled preclinical services to pharmaceutical, biotechnology, and academic customers, anchored by the world's largest human iPSC biobank of more than 2,500 individuals.
Ownership category
akta.pro rank

Greenstone Biosciences industry classification

Industry
Product category
Biotechnology Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • IPSC drug discovery
  • Organoid screening services
  • Human cell models
  • Preclinical safety testing
  • ADMET prediction platform

Where Greenstone Biosciences is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Greenstone Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. iPSC and Cell Products: Sale of standardized human iPSC lines, differentiated cells (cardiomyocytes, fibroblasts, smooth muscle cells, macrophages, endothelial cells, epithelial cells), and organoid products for research and drug discovery applications
  2. Custom Services: Customized services including PBMC collection and iPSC reprogramming, genetically engineered iPSCs, clinical trial in a dish, CARTOX hERG toxicity assays, hepatotoxicity screens, and specialized disease modeling
  3. Drug Discovery Partnerships: Strategic collaborations with pharmaceutical and biotech companies for drug discovery programs using human iPSC models and AI platforms

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goiPSC - Academia product line
Unit PricingPay-as-you-goDifferentiated cell products
Unit PricingPay-as-you-goOrganoid products
OtherMulti-year contractCustom services

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Greenstone Biosciences product offering

Product offering

Core offering

Greenstone Biosciences operates a human induced pluripotent stem cell (iPSC) drug discovery platform anchored by what it claims is the world's largest human iPSC biobank of 2,500+ individuals, including the largest collection of rare orphan disease iPSCs. It sells standardized iPSC lines, differentiated cell types, and 3D organoids, and provides contract research services spanning iPSC reprogramming, genome editing, high-throughput screening, ADMET-AI predictive analytics, and cardiac/hepatic safety assays for pharmaceutical and academic clients.

Product overview

Greenstone Biosciences operates as a biotech company offering a comprehensive platform of human iPSC-based products and services for drug discovery. The core offering centers on the world's largest human iPSC biobank (2,500+ individuals), which powers two main product lines: hiPSC-derived cells (ventricular/atrial cardiomyocytes, fibroblasts, smooth muscle cells, macrophages, endothelial cells, and intestinal epithelial cells) and 3D organoids (cardiac, pancreatic, gut organoids with vascularized variants). The portfolio is complemented by a suite of contract research services including iPSC reprogramming, custom differentiation, high-throughput screening, and specialized toxicity assays (CARTOX/hERG, hepatotoxicity). The ADMET-AI platform adds AI-powered predictive analytics for absorption, distribution, metabolism, excretion, and toxicity evaluation. Together, these products and services enable human-centric drug discovery that reduces reliance on animal testing and aligns with FDA New Approach Methodologies (NAMs) guidance.

Differentiator

Problem solved

Functional benefit

Products and services

  • ADMET-AI AI-powered platform for absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction using machine learning to accelerate drug candidate evaluation for pharmaceutical and biotech drug developers.
  • hiPSC-Derived Cells Human induced pluripotent stem cell-derived cell types including ventricular cardiomyocytes, atrial cardiomyocytes, fibroblasts, smooth muscle cells, macrophages, endothelial cells, and intestinal epithelial cells for disease modeling and drug discovery, sold to academic and pharmaceutical researchers.
  • Organoids 3D organ-like tissue models generated from iPSCs including ventricular cardiac organoids, atrial cardiac organoids, pancreatic islet organoids, gut organoids, vascularized ventricular cardiac organoids, and vascularized atrial cardiac organoids for disease modeling and drug discovery.
  • PBMC Collection and iPSC Reprogramming Collection of peripheral blood mononuclear cells and reprogramming into induced pluripotent stem cells for research and therapeutic applications, provided as a custom service to research and biotech clients.
  • Custom Differentiated iPSCs Custom differentiation services to generate specific cell types from iPSC lines for specialized research needs, delivered on a quote basis to academic and pharmaceutical clients.
  • Genetically Engineered iPSCs Genome editing services (CRISPR/Cas9 and related) to create genetically modified iPSC lines with specific mutations or modifications for disease modeling, sold to research and drug discovery clients.
  • High-Throughput Drug Discovery Scalable screening service using iPSC-derived cells and organoids for rapid drug candidate evaluation across multiple conditions, delivered to pharmaceutical and biotech clients.
  • Cell Village Panel of diverse iPSC lines representing population-scale genetic diversity for comprehensive drug testing, offered as a custom service for population-level drug response studies.
  • Clinical Trial in a Dish Personalized medicine service using patient-derived iPSCs to predict individual drug responses before clinical trials, delivered to pharmaceutical and biotech clients.
  • CARTOX (hERG Toxicity Assay) Cardiac safety screening service assessing hERG potassium channel blockade to predict drug-induced heart rhythm abnormalities, delivered to pharmaceutical preclinical safety teams.
  • Hepatotoxicity Screen Liver toxicity assessment service using human cellular models to predict drug-induced hepatotoxicity during drug development, sold to pharmaceutical preclinical safety teams.
  • Functional Assays of Gut Barrier Integrity and Disease Modelling Intestinal barrier function assessment and disease modeling service using gut organoids for gastrointestinal drug development, delivered to research and pharmaceutical clients.
  • Pancreatic Islet Organoid – Glucose Sensitivity Beta-cell function assessment service measuring glucose-stimulated insulin secretion responses in pancreatic islet organoids, delivered to diabetes and metabolic disease researchers.

Quantifiable outcome

  • Up to 92% of drugs fail in human trials despite preclinical testing in animals
  • +1 more outcomes

Companies that use Greenstone Biosciences

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Greenstone Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Greenstone Biosciences partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and strategic.

  • Intel Corp.coreTechnology or Integration · 2 June 2026Strategic collaboration to scale human-centric drug discovery by integrating Greenstone's induced pluripotent stem cell biobank with Intel's Edge AI computing and infrastructure. The partnership aims to accelerate AI-enabled drug discovery, improve drug safety assessment, and advance precision medicine, highlighted during Intel's Computex 2026 keynote.
  • Neolaia BiostrategicStrategic or Co-development Partner · 19 February 2026Strategic collaboration to advance inflammatory bowel disease (IBD) drug development using iPSC-derived macrophages and patient-relevant human gut organoid models. Neolaia provides proprietary drug candidates while Greenstone evaluates them using its human-based disease modeling platform.
  • Cibus TherapeuticsstrategicStrategic or Co-development Partner · 19 December 2025Partnership with Mission: Cure and Greenstone Biosciences to advance CBT-101, a novel therapy for chronic pancreatitis. The collaboration combines drug development, stem cell AI-based discovery, and patient advocacy, aiming to begin clinical trials in 2026.
  • Creative Medical Technology HoldingsstrategicStrategic or Co-development Partner · 30 October 2025Partnership for the BioDefense Veterans Initiative to address health issues caused by toxic burn pit exposure among U.S. veterans. Greenstone provides molecular and cellular data analysis systems to develop predictive models and treatments using AI-integrated regenerative biodefense.
  • NVIDIAcoreTechnology or Integration · 25 October 2025Collaboration to develop AI models predicting drug toxicity using human cellular systems. The project aims to enhance drug safety testing, reduce reliance on animal testing, and advance precision therapeutics, aligning with FDA's strategic shift to new methodologies.
  • IlluminacoreTechnology or Integration · 24 October 2025Collaboration to advance precision drug discovery by integrating Greenstone's iPSC biobank with Illumina's genomics technologies. The partnership aims to generate detailed molecular maps to enhance understanding of disease biology and accelerate drug development across multiple therapeutic areas.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Greenstone Biosciences competitors and assessment

Company assessment

Direct peers

  • Insitro: Insitro combines iPSC-derived disease models with machine learning to drive drug discovery partnerships with pharma. It mirrors Greenstone's strategy of integrating iPSC biology, AI/ML, and pharma discovery collaborations, and overlaps on ADMET prediction and target ID workflows.
  • Ncardia: Ncardia provides human iPSC-derived cell products and services, including iPSC-derived cardiomyocytes, used for cardiac safety and drug discovery. It directly competes with Greenstone's ventricular/atrial cardiomyocytes, CARTOX/hERG assays, and cardiovascular disease modeling offerings.
  • BrainXell: BrainXell specializes in iPSC-derived neural cell types for CNS disease modeling and drug discovery. Like Greenstone, it serves academic researchers and pharma with custom differentiated iPSCs, overlapping with Greenstone's broader cell-type catalog and target identification services.
  • Emulate Inc. Emulate offers organ-on-chip and micro-physiological systems used for human-relevant preclinical drug testing. Its organ-Chip platform competes directly with Greenstone's organoid systems for ADMET, hepatotoxicity, and gut barrier integrity services.
  • Bit.bio: Bit.bio has developed an iPSC reprogramming and cell-coding platform that produces human cell types at scale for research and drug discovery. Its deterministic reprogramming approach competes directly with Greenstone's iPSC biobank, custom differentiated iPSCs, and Cell Village offerings.
  • Cellular Dynamics (FUJIFILM): Cellular Dynamics International, now part of FUJIFILM, is the established leader in commercial iPSC-derived cell products including iCell cardiomyocytes. It is the incumbent against which Greenstone's $200 academic iPSC vials and differentiated cell products are differentiated.
  • Axol Bioscience: Axol Bioscience manufactures iPSC-derived cell products including cardiomyocytes, neurons, and endothelial cells for disease modeling and drug discovery. Its iPSC-derived cell catalog, especially cardiac and neuronal lines, directly overlaps with Greenstone's hiPSC-Derived Cells and organoid product lines.

Broad incumbents

  • CytoReason: CytoReason provides AI-driven multi-omics data analysis and disease models for pharma R&D, used to accelerate drug discovery and target identification. Its AI/omics platform overlaps with Greenstone's ADMET-AI and Bioinformatics/Multi-Omics positioning for enterprise pharma customers.
  • Recursion Pharmaceuticals: Recursion is a publicly listed AI-driven drug discovery platform combining high-throughput biology with proprietary ML. Its larger scale and broader pipeline make it a broad incumbent against Greenstone's AI-drug-discovery ambitions, especially in partnership pitches to large pharma.

Emerging players

  • Xilis: Xilis has built a micro-organoid platform for patient-derived drug screening and predictive oncology. While oncology-focused, its micro-organoid platform parallels Greenstone's 3D organoid drug-discovery offering and competes for pharma discovery service budgets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Greenstone Biosciences social profiles

Digital presence

Greenstone Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Greenstone Biosciences leadership team

Management profile

Number of profiles

Profiles2 records

Greenstone Biosciences funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Greenstone Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Greenstone Biosciences

What does Greenstone Biosciences do?

Greenstone Biosciences operates a human induced pluripotent stem cell (iPSC) drug discovery platform anchored by what it claims is the world's largest human iPSC biobank of 2,500+ individuals, including the largest collection of rare orphan disease iPSCs. It sells standardized iPSC lines, differentiated cell types, and 3D organoids, and provides contract research services spanning iPSC reprogramming, genome editing, high-throughput screening, ADMET-AI predictive analytics, and cardiac/hepatic safety assays for pharmaceutical and academic clients.

Is Greenstone Biosciences a public or private company?

Greenstone Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Greenstone Biosciences founded?

Greenstone Biosciences was founded in 2022. It employs 11 to 50 people.

Where is Greenstone Biosciences based?

Greenstone Biosciences is headquartered in Palo Alto, United States, in the North America region.

How does Greenstone Biosciences make money?

Three revenue lines are on record. iPSC and Cell Products are the primary driver. The others are custom Services and drug Discovery Partnerships.

Who are Greenstone Biosciences's main competitors?

Direct peers on record are Insitro, Ncardia, BrainXell, Emulate Inc., Bit.bio, Cellular Dynamics (FUJIFILM) and Axol Bioscience. Broad incumbents are CytoReason and Recursion Pharmaceuticals. Xilis is listed as an emerging player.

Does Greenstone Biosciences have an API?

No public API is recorded for Greenstone Biosciences.

What industry is Greenstone Biosciences in?

Greenstone Biosciences's product category is Biotechnology Drug Discovery Services. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyGreenstone bets on human cells to fix DMD heartsGreenstone Biosciences received an NIH R61 grant to develop drugs for Duchenne muscular dystrophy cardiomyopathy using human iPSC-derived cardiomyocytes and AI, bypassing mouse models. The program targets myocardial fibrosis, the leading cause of death in DMD patients, with a follow-on R33 award pending. The initiative aligns with FDA's 2025 roadmap to reduce animal testing.FinSMEsGreenstone Biosciences Receives Breakthrough T1D GrantGreenstone Biosciences received a Breakthrough T1D grant, with the amount undisclosed. The company will use the funds to develop a T1D-derived islet cell platform, create iPSCs from T1D patients, build 3D pancreatic islet organoids, and apply multi-omics technologies to study insulin-producing β cells.BioSpaceGreenstone Biosciences Awarded Breakthrough T1D Grant to Advance Islet Cell PlatformGreenstone Biosciences received a Breakthrough T1D grant to develop a T1D-derived islet cell platform for studying and protecting insulin-producing β cells. The project will create iPSCs from diverse T1D patients and 3D pancreatic islet organoids, using multi-omics to identify vulnerable pathways. The iPSC lines will be banked as a renewable resource with public data sharing.FinancialContent Business PageGreenstone Biosciences Awarded Breakthrough T1D Grant to Advance Islet Cell PlatformGreenstone Biosciences has been awarded a Breakthrough T1D Industry Discovery and Development Partnership grant to develop an islet cell platform for type 1 diabetes research. The project involves creating induced pluripotent stem cells from patients to build 3D pancreatic islet organoids, aiming to identify therapeutic targets and understand beta cell vulnerability. This initiative seeks to address the limitations of current animal models by providing a scalable human-centric discovery engine.Breakthrought1DGreenstone Biosciences Awarded Breakthrough T1D Grant to Advance Type 1 Diabetes-Derived Islet Cell Platform for Research and DevelopmentGreenstone Biosciences received a Breakthrough T1D grant to develop a type 1 diabetes-derived islet cell platform using patient iPSCs. The project will generate 3D pancreatic islet organoids to study β-cell vulnerability and identify therapeutic targets. All iPSC lines will be banked as a renewable resource for future research.BioPharma DiveGreenstone Biosciences Awarded Breakthrough T1D Grant to Advance Type 1 Diabetes (T1D)-Derived Islet Cell Platform for Research and DevelopmentGreenstone Biosciences received a Breakthrough T1D grant to develop a T1D-derived islet cell platform for research. The project will generate iPSCs from T1D patients into 3D pancreatic islet organoids to study β cell vulnerability. The iPSC lines will be banked as a renewable resource for future research.Longevity.TechnologyGreenstone receives NIH R61 grant for cardiac fibrosisGreenstone Biosciences has received a Catalyze R61 award from the NIH's National Heart, Lung, and Blood Institute to develop drug candidates targeting cardiac fibrosis and dilated cardiomyopathy in Duchenne muscular dystrophy. The program will utilize advanced models, proteomics, computational screening, and AI to identify and validate treatments, with a focus on addressing unmet needs in heart disease for DMD patients.Pulse 2.0Greenstone Biosciences Receives NIH Grant To Develop Cardiac Fibrosis Treatments For Duchenne Muscular DystrophyGreenstone Biosciences received a Catalyze R61 award from the National Heart, Lung, and Blood Institute to develop treatments for cardiac fibrosis in Duchenne muscular dystrophy patients. The grant supports target identification and early drug candidate discovery using induced pluripotent stem cell models and generative AI. This initiative addresses a significant unmet medical need as no approved therapies currently exist for this specific complication of DMD.BioSpaceGreenstone Biosciences Receives NIH R61 Grant to Advance Cardiac Fibrosis Therapeutics for Duchenne Muscular DystrophyGreenstone Biosciences received a Catalyze R61 award from the NIH to discover drug candidates for myocardial fibrosis and cardiomyopathy in Duchenne muscular dystrophy. The program uses iPSC models and AI to identify candidates, with a potential R33 phase for in vivo testing. The award addresses a disease where no approved therapy directly targets heart scarring.FinancialContent Business PageGreenstone Biosciences Receives NIH R61 Grant to Advance Cardiac Fibrosis Therapeutics for Duchenne Muscular DystrophyGreenstone Biosciences has received a Catalyze R61 award from the National Heart, Lung, and Blood Institute (NHLBI), part of the NIH, to fund a drug discovery program targeting myocardial fibrosis and dilated cardiomyopathy in Duchenne muscular dystrophy (DMD). The program will use the company's iPSC biobank and cardiomyocyte disease models combined with proteomics, computational drug screening, and generative AI, structured across two phases: R61 for target identification and R33 for in vivo compound testing. The award coincides with growing regulatory support for New Approach Methodologies, including the FDA's 2025 Roadmap to Reduce Animal Testing and the advancing FDA Modernization Act 3.0.